This is the authors' abstract. We don't add key points for this paper.
Abstract Objective: To explore the clinical efficacy of interventional treatment combined with targeted therapy and immune checkpoint inhibitors(ICIs) in patients with postoperative recurrence of dual-phenotype hepatocellular carcinoma(DPHCC). Methods: A retrospective study was conducted on the clinical data of 8 patients with postoperative recurrence of dual-phenotype hepatocellular carcinoma treated at Xiamen Traditional Chinese Medicine Hospital from January 2019 to March 2023. The clinical outcomes such as progression-free survival and overall survival after comprehensive treatment were analyzed and evaluated. Results: All 8 patients received transcatheter arterial chemoembolization(TACE) or hepatic Artery InfusionChemotherapy(HAIC) combined with immune checkpoint inhibitors(ICIs) and anti-angiogenic drugs, with a median survival time of 4.9 months (range 1-57.2 months) and a median progression-free survival of 1.5 months (range 0-21 months). Except for patients 2 and 4, tumors continued to progress in all cases, resulting in a disease control rate of only 25%. Conclusion: The efficacy of TACE/HAIC combined with ICIs and targeted drugs for treating dual-phenotype hepatocellular carcinoma may be limited.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: